The only thing mentioning these two together is he
Post# of 152216
https://academic.oup.com/jac/advance-article/...chresult=1
“ Many antiretrovirals now have the potential to be administered in these ways, such as cabotegravir, rilpivirine, leronlimab, islatravir ...”
Maybe multi drug resistant for long acting but I’m assuming they aren’t targeting that just yet. They probably just want to use any drug that can extend CAB to that 4/6 month mark.

